Browse TOP2A

Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus, nucleoplasm Note=Generally located in the nucleoplasm.
Domain PF00204 DNA gyrase B
PF00521 DNA gyrase/topoisomerase IV
PF08070 DTHCT (NUC029) region
PF02518 Histidine kinase-
PF01751 Toprim domain
PF16898 C-terminal associated domain of TOPRIM
Function

Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000712 resolution of meiotic recombination intermediates
GO:0000819 sister chromatid segregation
GO:0002244 hematopoietic progenitor cell differentiation
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006265 DNA topological change
GO:0006266 DNA ligation
GO:0006268 DNA unwinding involved in DNA replication
GO:0006310 DNA recombination
GO:0006312 mitotic recombination
GO:0006323 DNA packaging
GO:0006921 cellular component disassembly involved in execution phase of apoptosis
GO:0007059 chromosome segregation
GO:0007093 mitotic cell cycle checkpoint
GO:0007126 meiotic nuclear division
GO:0007127 meiosis I
GO:0007131 reciprocal meiotic recombination
GO:0007346 regulation of mitotic cell cycle
GO:0007623 circadian rhythm
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0030261 chromosome condensation
GO:0030262 apoptotic nuclear changes
GO:0030263 apoptotic chromosome condensation
GO:0031570 DNA integrity checkpoint
GO:0032392 DNA geometric change
GO:0032508 DNA duplex unwinding
GO:0035825 reciprocal DNA recombination
GO:0039692 single stranded viral RNA replication via double stranded DNA intermediate
GO:0039694 viral RNA genome replication
GO:0039703 RNA replication
GO:0040016 embryonic cleavage
GO:0042752 regulation of circadian rhythm
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044033 multi-organism metabolic process
GO:0044774 mitotic DNA integrity checkpoint
GO:0045069 regulation of viral genome replication
GO:0045070 positive regulation of viral genome replication
GO:0045091 regulation of single stranded viral RNA replication via double stranded DNA intermediate
GO:0045132 meiotic chromosome segregation
GO:0045786 negative regulation of cell cycle
GO:0045870 positive regulation of single stranded viral RNA replication via double stranded DNA intermediate
GO:0045930 negative regulation of mitotic cell cycle
GO:0048511 rhythmic process
GO:0048524 positive regulation of viral process
GO:0050792 regulation of viral process
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051304 chromosome separation
GO:0051307 meiotic chromosome separation
GO:0051321 meiotic cell cycle
GO:0071103 DNA conformation change
GO:0097194 execution phase of apoptosis
GO:0098813 nuclear chromosome segregation
GO:1903046 meiotic cell cycle process
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
Molecular Function GO:0000287 magnesium ion binding
GO:0003682 chromatin binding
GO:0003916 DNA topoisomerase activity
GO:0003918 DNA topoisomerase type II (ATP-hydrolyzing) activity
GO:0005080 protein kinase C binding
GO:0008022 protein C-terminus binding
GO:0008094 DNA-dependent ATPase activity
GO:0008144 drug binding
GO:0008301 DNA binding, bending
GO:0016853 isomerase activity
GO:0016887 ATPase activity
GO:0032182 ubiquitin-like protein binding
GO:0042623 ATPase activity, coupled
GO:0042826 histone deacetylase binding
GO:0043130 ubiquitin binding
GO:0046982 protein heterodimerization activity
GO:0061505 DNA topoisomerase II activity
Cellular Component GO:0000793 condensed chromosome
GO:0005813 centrosome
GO:0005814 centriole
GO:0009330 DNA topoisomerase complex (ATP-hydrolyzing)
GO:0019035 viral integration complex
GO:0044450 microtubule organizing center part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-1538133: G0 and Early G1
R-HSA-392499: Metabolism of proteins
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-597592: Post-translational protein modification
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-4615885: SUMOylation of DNA replication proteins
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TOP2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TOP2A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TOP2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4260.226
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0720.97
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6990.669
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6840.195
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4430.826
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0020.726
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1130.806
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5560.78
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4980.809
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3540.776
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4220.828
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4690.00053
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TOP2A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 594011.128.90.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TOP2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TOP2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TOP2A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TOP2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TOP2A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TOP2A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTOP2A
Nametopoisomerase (DNA) II alpha
Aliases TOP2; topoisomerase (DNA) II alpha 170kDa; TP2A; DNA gyrase; DNA topoisomerase (ATP-hydrolyzing); DNA topois ......
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TOP2A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TOP2A.
ID Name Drug Type Targets #Targets
DB00218MoxifloxacinSmall MoleculeTOP2A1
DB00276AmsacrineSmall MoleculeALB, KCNH2, ORM1, TOP2A4
DB00380DexrazoxaneSmall MoleculeTOP2A, TOP2B2
DB00385ValrubicinSmall MoleculeTOP2A1
DB00444TeniposideSmall MoleculeTOP2A1
DB00445EpirubicinSmall MoleculeCHD1, TOP2A2
DB00467EnoxacinSmall MoleculeTOP2A1
DB00487PefloxacinSmall MoleculeTOP2A1
DB00537CiprofloxacinSmall MoleculeKCNH2, TOP2A2
DB00685TrovafloxacinSmall MoleculeTOP2A1
DB00694DaunorubicinSmall MoleculeTOP2A, TOP2B2
DB00773EtoposideSmall MoleculeTOP2A, TOP2B2
DB00970DactinomycinSmall MoleculeTOP2A, TOP2B2
DB00978LomefloxacinSmall MoleculeTOP2A1
DB00997DoxorubicinSmall MoleculeNOLC1, TOP2A2
DB01059NorfloxacinSmall MoleculeTOP2A1
DB01137LevofloxacinSmall MoleculeTOP2A1
DB01165OfloxacinSmall MoleculeTOP2A1
DB01177IdarubicinSmall MoleculeTOP2A1
DB01179PodofiloxSmall MoleculeTOP2A, TUBA4A, TUBB3
DB01204MitoxantroneSmall MoleculeTOP2A1
DB01208SparfloxacinSmall MoleculeTOP2A1
DB01645GenisteinSmall MoleculeAKT1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GPER1, NCOA1, NCOA2, NR1I2 ......13
DB04576FleroxacinSmall MoleculeTOP2A1
DB04967LucanthoneSmall MoleculeAPEX1, TOP1, TOP2A3
DB04975BanoxantroneSmall MoleculeTOP2A1
DB04978SP1049CSmall MoleculeTOP2A1
DB05022AmonafideSmall MoleculeTOP2A, TOP2B2
DB05129ElsamitrucinSmall MoleculeTOP1, TOP2A2
DB0570613-deoxydoxorubicinSmall MoleculeTOP2A1
DB05920RTA 744Small MoleculeTOP2A1
DB06013AldoxorubicinSmall MoleculeTOP2A1
DB06042ZEN-012Small MoleculeTOP2A, TOP2B, TUBB, TUBB1, TUBB3, TUBB4A6
DB06263AmrubicinSmall MoleculeTOP2A1
DB06362BecatecarinSmall MoleculeTOP2A, TOP2B2
DB06420AnnamycinSmall MoleculeTOP2A1
DB06421DeclopramideSmall MoleculeTOP2A, TOP2B2
DB09047FinafloxacinSmall MoleculeTOP2A1